Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Gilteritinib Fumarate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 49,603Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Gilteritinib as Maintenance Therapy Shows Benefit in Subgroups of FLT3-ITD
    Gilteritinib as Maintenance Therapy Shows Benefit in Subgroups of FLT3-ITD

    09 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/gilteritinib-as-maintenance-therapy-demonstrated-benefit-in-subgroups-of-flt3-itd-acute-myeloid-leukemia-patients-301846826.html

    PR NEWSWIRE
    09 Jun 2023
    Share Share
    Astellas Xospata comes up short again in bid to expand leukemia use
    Astellas Xospata comes up short again in bid to expand leukemia use

    10 Mar 2023

    // Kevin Dunleavy FIERCE PHARMA

    https://www.fiercepharma.com/pharma/astellas-xospata-comes-short-again-bid-expand-label

    Kevin Dunleavy FIERCE PHARMA
    10 Mar 2023
    Share Share
    Astellas and BMT CTN Announce Results from PIII MORPHO Trial of Gilteritinib
    Astellas and BMT CTN Announce Results from PIII MORPHO Trial of Gilteritinib

    09 Mar 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/astellas-and-bmt-ctn-announce-topline-results-from-phase-3-morpho-trial-of-gilteritinib-301767481.html

    PR NEWSWIRE
    09 Mar 2023
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Gilteritinib Fumarate Tablets
    FDA Confirms Paragraph IV Patent Litigation for Gilteritinib Fumarate Tablets

    13 Feb 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-gilteritinib-fumarate-tablets-13638.pdf

    FDA
    13 Feb 2023
    Share Share
    Kronos Begins Dosing in PIb/II Trial of Lanraplenib with Gilteritinib
    Kronos Begins Dosing in PIb/II Trial of Lanraplenib with Gilteritinib

    22 Aug 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/08/22/2502156/0/en/Kronos-Bio-Announces-First-Patient-Dosed-in-Phase-1b-2-Clinical-Trial-of-Lanraplenib-in-Combination-with-Gilteritinib-in-Acute-Myeloid-Leukemia.html

    GLOBENEWSWIRE
    22 Aug 2022
    Share Share
    Gilteritinib clinical activity in r/r FLT3 mutated AML
    Gilteritinib clinical activity in r/r FLT3 mutated AML

    12 Jan 2022

    // ONLINELIBRARY

    https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.26447

    ONLINELIBRARY
    12 Jan 2022
    Share Share